• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Evaluation of Cardiovascular Disease Risk in HIV-1 –Infected Patients Treated with Darunavir
ConclusionsThis comprehensive review of Janssen-sponsored clinical trial, post-marketing, and epidemiological data does not suggest that CVD should be considered an important risk for users of darunavir.
Source: Drugs in R&D - September 1, 2018 Category: Drugs & Pharmacology Source Type: research

Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study
Publication date: June 2018Source: The Lancet HIV, Volume 5, Issue 6Author(s): Lene Ryom, Jens D Lundgren, Wafaa El-Sadr, Peter Reiss, Ole Kirk, Matthew Law, Andrew Phillips, Rainer Weber, Eric Fontas, Antonella d' Arminio Monforte, Stéphane De Wit, Francois Dabis, Camilla I Hatleberg, Caroline Sabin, Amanda Mocroft, D:A:D study groupSummaryBackgroundAlthough earlier protease inhibitors have been associated with increased risk of cardiovascular disease, whether this increased risk also applies to more contemporary protease inhibitors is unknown. We aimed to assess whether cumulative use of ritonavir-boosted atazanavir and...
Source: The Lancet HIV - July 10, 2018 Category: Infectious Diseases Source Type: research

Evaluation of Cardiovascular Disease Risk in HIV-1 –Infected Patients Treated with Darunavir
ConclusionsThis comprehensive review of Janssen-sponsored clinical trial, post-marketing, and epidemiological data does not suggest that CVD should be considered an important risk for users of darunavir.
Source: Drugs in R&D - July 10, 2018 Category: Drugs & Pharmacology Source Type: research

Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study
Publication date: June 2018Source: The Lancet HIV, Volume 5, Issue 6Author(s): Lene Ryom, Jens D Lundgren, Wafaa El-Sadr, Peter Reiss, Ole Kirk, Matthew Law, Andrew Phillips, Rainer Weber, Eric Fontas, Antonella d' Arminio Monforte, Stéphane De Wit, Francois Dabis, Camilla I Hatleberg, Caroline Sabin, Amanda Mocroft, D:A:D study groupSummaryBackgroundAlthough earlier protease inhibitors have been associated with increased risk of cardiovascular disease, whether this increased risk also applies to more contemporary protease inhibitors is unknown. We aimed to assess whether cumulative use of ritonavir-boosted atazanavir and...
Source: The Lancet HIV - July 5, 2018 Category: Infectious Diseases Source Type: research